Affordable Access

Access to the full text

Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis

  • Lough, Tony1
  • Luo, Qingyang1
  • Luxmanan, Carthika1, 2
  • Anderson, Alastair1
  • Suttie, Jimmy1
  • O’Sullivan, Paul1, 3
  • Darling, David1
  • 1 Pacific Edge Limited, 87 St David Street, Dunedin, 9016, New Zealand , Dunedin (New Zealand)
  • 2 University of Otago, Dunedin, New Zealand , Dunedin (New Zealand)
  • 3 Merck, Sharpe & Dohme, Auckland, New Zealand , Auckland (New Zealand)
Published Article
BMC Urology
Springer (Biomed Central Ltd.)
Publication Date
Mar 09, 2018
DOI: 10.1186/s12894-018-0327-6
Springer Nature


BackgroundThe non-invasive Cxbladder urine test system has demonstrated clinical utility in ruling out urothelial carcinoma (UC) in patients with asymptomatic microscopic hematuria (AMH), suggesting that the number of invasive diagnostic tests, including cystoscopy, used in this patient population may be reduced by Cxbladder testing prior to conducting a full urological work-up. The aim of this study was to demonstrate the enhanced clinical utility of communicating objective information on diagnostic decisions made by individual physicians on individual patients with AMH.MethodsThree hundred ninety-six physician-patient decisions were generated from twelve participant physicians evaluating real world case notes from the same 33 patients presenting with AMH. Each physician reviewed and recommended diagnostic tests and procedures based on each patient’s referral data and then re-evaluated their clinical recommendation following disclosure of the non-invasive Cxbladder urine test result. Changes assessed were the total number of requested diagnostic procedures and the number of invasive procedures, including cystoscopy, following addition of information from Cxbladder in the Triage and Triage and Detect modalities.ResultsPhysicians made significant changes to their diagnostic behavior for patients with AMH when presented with Cxbladder test results, including a reduction in the number of total and invasive procedures including cystoscopy for individuals identified as having a low probability of UC. The intensity of investigation was targeted and increased, including use of total procedures and cystoscopy, for patients identified by Cxbladder tests as having a high probability of UC: urologists increased the level of investigation for both total procedures and invasive procedures. The outcome resulted in patients with a high risk of UC receiving appropriate guideline-recommended invasive diagnostic tests. Patients who tested negative were offered fewer and significantly less invasive procedures. This change in physician behavior results in an increased clinical and patient utility, lower risk of missed UC and invasive test-related harm incidents.ConclusionsThis study demonstrated the potential for increased clinical resolution and significantly enhanced patient management, when physicians consider Cxbladder test results in their clinical evaluation. The change in physician behavior led to more appropriate diagnostic procedure selection and resource allocation to the benefit of both patients and healthcare systems.

Report this publication


Seen <100 times